Charles River officer proposes $1.73M share sale

The notice lists 4,300 shares acquired as RSUs and PSUs and 2,345 shares from a stock option exercise.

Accepted by SEC EDGAR 08/06/2026 - 03:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Charles River Laboratories International, Inc. (CRL) lists a Form 144 notice from Michael Knell, an officer, for the proposed sale of 6,645 common shares with an aggregate market value of $1,727,700. The approximate sale date is August 6, 2026. The notice states that 48,167,730 common shares were outstanding.

Key Figures

Proposed shares for sale: 6,645 shares Aggregate Market Value: $1,727,700 Common shares outstanding: 48,167,730 shares +2 more

5 metrics

Proposed shares for sale 6,645 shares Common stock; approximate sale date August 6, 2026

Aggregate Market Value $1,727,700 Proposed sale

Common shares outstanding 48,167,730 shares As stated in the notice

Shares acquired as RSUs and PSUs 4,300 shares Acquired January 28, 2022

Shares from stock option exercise 2,345 shares Dated August 6, 2026

Key Terms

RSUs, PSUs, Stock Option Exercise, Aggregate Market Value

4 terms

RSUs financial

"RSUs & PSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

PSUs financial

"RSUs & PSUs"

PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.

Stock Option Exercise financial

"Nature of Acquisition Transaction"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CRL shares is Michael Knell proposing to sell?

Michael Knell, an officer of Charles River Laboratories International, Inc., reported a proposed sale of 6,645 common shares, with an aggregate market value of $1,727,700. The approximate sale date is August 6, 2026.

How did Michael Knell acquire the CRL shares listed for sale?

The notice lists 4,300 shares acquired as RSUs and PSUs on January 28, 2022, and 2,345 shares from a stock option exercise dated August 6, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001543779
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Charles River Laboratories International, Inc.
SEC File Number	001-15943
Address of Issuer	251 Ballardvale Street Wilmington MASSACHUSETTS 01887
Phone	4242153534
Name of Person for Whose Account the Securities are To Be Sold	Michael Knell
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	6645	1727700	48167730	08/06/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/28/2022	RSUs & PSUs	Charles River Laboratories International, Inc.			4300	08/06/2026	Cash
Common	08/06/2026	Stock Option Exercise	Charles River Laboratories International, Inc.			2345	08/06/2026	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/JOSEPH CASSIDY, for UBS Financial Services Inc, as attorney-in-fact for Michael Knell
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)